Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

trol of Tissue Contouring with an

Extracellular pH-Modulated Enzyme" pre-clinical data

-- American Diabetes Association - June 6-10th - presentation on

"Pharmacokinetics and Glucodynamics of an Insulin Analog Injected with

Recombinant Human Hyaluronidase" Phase I clinical data

-- 6th World Congress of the International Academy of Cosmetic

Dermatology - June 18-20th - podium presentation of "Temporal-Spatial

Control of Tissue Contouring with an Extracellular pH-Modulated

Enzyme" expanded pre-clinical data

First Quarter 2008 Financial Results

-- Net loss for the first quarter of 2008 was $10.0 million, or $0.13 per

share, compared with a net loss for the first quarter of 2007 of

$3.4 million, or $0.05 per share.

-- Revenues for the first quarter of 2008 were $1.8 million, compared

with $810,000 for the first quarter of 2007. Cumulase product sales

for the first quarter of 2008 were $127,000, compared with $171,000

for the first quarter of 2007. Revenues under collaborative

agreements for the first quarter of 2008 were $1.7 million, compared

with $623,000 for the first quarter of 2007. Revenues under

collaborative agreements in 2008 primarily consisted of the

amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter of

$452,000 and Roche of $624,000.

-- Research and development expenses for the first quarter of 2008 were

$8.4 million, compared with $2.8 million for the first quarter of

2007, reflecting increased compensation expenses including share-based

compensation expenses, research and development spending on our

Insulin, Bisphosphonates, and PEG PH20 clinical and pre-clinical

programs, and production costs associated with the manu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 With ... increase of personal health expenditure as well as ... care system, China diagnostic reagent industry has been ... over 90%. In 2013, Chinese in vitro diagnostics ... billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 BCC ... Global Markets for Enzymes in Industrial Applications , ... reach to nearly $7.1 billion by 2018, registering a ... growth is estimated to be recorded in the detergent ... forecast period. , Enzyme technology has influenced almost every ...
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Fla. , July 30, 2014  Dyadic ... biotechnology company whose patented and proprietary technologies are ... and other proteins for the bioenergy, bio-based chemical, ... appointment of Thomas "Tom" Dubinski as Vice President ... for leading the financial and information technology operations ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... the American Academy ... of Dermatology, FREEPORT, N.Y., ... and its natural receptor,OCTN- 1, are a natural part of the skin,s ... in photoaged,skin. The data was presented at the Poster Session at the ...
... Feb. 11 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... delivery of therapeutic molecules using its,eligen(R) technology, today announced ... CEO & Investor Conference on February 12, 2008 on,its ... page of the,Emisphere Web site at http://www.emisphere.com/ir.asp ...
... On Monday, January 28, The Royal,Marsden Hospital ... Modulated Arc Therapy (VMAT)* treatment in the ... the treatment, the hospital,used its existing Elekta ... control system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ...
Cached Biology Technology:AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skin's Natural Antioxidant System 2Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12 2Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... Molecular Biology, today publishes its Honey Bee Genome Special ... long-awaited Honey Bee Genome Sequence, published earlier this week ... Sequencing Project (HBGSP), a large scale communal project led ... National Human Genome Research Institute, is expected to usher ...
... Cancer Center at Thomas Jefferson University in Philadelphia and at ... found evidence suggesting that a mutation in a gene that ... a role in the initiation of a major form of ... Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at ...
... of a cell is all about growing and dividing at ... one of the most tightly regulated cellular processes. A control ... cell cycle machinery are produced, activated and degraded to make ... work differently and are usually studied separately, but researchers at ...
Cached Biology News:Looking to a new era in bee research 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 3How nature tinkers with the cellular clock 2
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... efficient enrichment of functional endoplasmic reticulum ... culture. The isolated ER are useful ... pathway analysis. Metabolic abnornalities of ER ... cystic fibrosis and many more ER ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... stabilizing 400g of purified RNA samples., , ... stabilization of aqueous RNA samples that have ... guanidine, phenol/chloroform, silica, oligo dT etc or ... all the necessary components for the stabilization ...
Biology Products: